HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Toshio Konishi Tamiyuki Ohbayashi Tatsuo Kaneko Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Konishi, T. Articles by Yamato, Y. Search for Related Content PubMed PubMed Citation Articles by Konishi, T. Articles by Yamato, Y.

Ann Thorac Surg 1993;56:101-103
© 1993 The Society of Thoracic Surgeons

---

Articles

Preoperative use of erythropoietin for cardiovascular operations in anemia

Divisions of Cardiovascular Surgery and Anesthesiology, Gunma Prefectural Maebashi Hospital, Gunma, Japan

Accepted for publication October 9, 1992.

^_* Address reprint requests to Dr Konishi, Division of Cardiovascular Surgery, Gunma Prefectural Maebashi Hospital, Kou 3-12, Kameizumi Maebashi-City, Gunma, 371, Japan.

Erythropoietin was used in 10 patients undergoing elective cardiovascular operations who were compromised with anemia. Initially, their blood hemoglobin levels were less than 10 g/dL (range, 7.5 to 9.9 g/dL). Erythropoietin (600 to 700 units/kg per week) was administered intravenously or subcutaneously for about 2 to 12 weeks. Blood hemoglobin levels increased in each patient (11.0 to 14.5 g/dL) until the day of operation, and during this course autologous blood donations (400 to 1,200 mL) were obtained from 8 patients. As a result, homologous blood transfusions were needed in only 1 patient in whom erythropoietin treatment was interrupted for other reasons. All these patients were discharged without event, and no adverse effects due to erythropoietin were found. Although the causes of anemia were not specified in some of these patients, it was noteworthy that erythropoietin was effective even in a patient with hypoplastic bone marrow. Subcutaneous use was assumed to be especially favorable in managing anemic patients, in whom preoperative erythropoietin treatment could be continued for up to 82 days. We conclude that erythropoietin would be beneficial for the anemic population to secure homologous-blood-free operations.

This article has been cited by other articles:

				R. J. Sommer, Z. M. Hijazi, and J. F. Rhodes Jr Pathophysiology of Congenital Heart Disease in the Adult: Part I: Shunt Lesions Circulation, February 26, 2008; 117(8): 1090 - 1099. [Full Text] [PDF]

				V. Casati, A. D'Angelo, L. Barbato, D. Turolla, F. Villa, M. A. Grasso, A. Porta, and F. Guerra Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery Br. J. Anaesth., September 1, 2007; 99(3): 349 - 352. [Abstract] [Full Text] [PDF]

				L. YazicioGlu, S. Eryilmaz, M. Sirlak, M. B. Inan, A. Aral, R. Tasoz, N. T. Eren, B. Kaya, and H. Akalin Recombinant human erythropoietin administration in cardiac surgery J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 741 - 745. [Abstract] [Full Text] [PDF]

				H. Kiyama, N. Ohshima, T. Imazeki, and T. Yamada Autologous blood donation with recombinant human erythropoietin in anemic patients Ann. Thorac. Surg., November 1, 1999; 68(5): 1652 - 1656. [Abstract] [Full Text] [PDF]